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Abstract
 
A variety of data suggest that in vivo production of interferon (IFN)-
 
 
 
 is necessary, but not
sufficient, for expression of secondary protective immunity against intracellular pathogens. To
discover specific IFN-
 
 
 
–independent T cell mediated mechanisms, we took advantage of an in
vitro culture system that models in vivo immune responses to the intracellular bacterium 
 
Fran-
cisella tularensis
 
 live vaccine strain (LVS). LVS-immune lymphocytes specifically controlled 99%
of the growth of LVS in wild-type murine bone marrow–derived macrophages. Surprisingly,
LVS-immune lymphocytes also inhibited LVS intracellular growth by as much as 95% in mac-
rophages derived from IFN-
 
 
 
 receptor knockout (IFN
 
 
 
R KO) mice. CD8
 
 
 
 T cells, and to a
lesser degree CD4
 
 
 
 T cells, controlled LVS intracellular growth in both wild-type and IFN
 
 
 
R
KO macrophages. Further, a unique population of Thy1
 
 
 
  
 
 
 
CD4
 
 
 
CD8
 
 
 
 cells that was pre-
viously suggested to operate during secondary immunity to LVS in vivo strongly controlled
LVS intracellular growth in vitro. A large proportion of the inhibition of LVS intracellular
growth in IFN
 
 
 
R KO macrophages by all three T cell subsets could be attributed to tumor ne-
crosis factor (TNF) 
 
 
 
. Thus, T cell mechanisms exist that control LVS intracellular growth
without acting through the IFN-
 
 
 
 receptor; such control is due in large part to TNF-
 
 
 
, and is
partially mediated by a unique double negative T cell subpopulation.
Key words: protective immunity • 
 
Francisella tularensis
 
 LVS • interferon 
 
 
 
 • TNF-
 
 
 
 • T cells
 
Introduction
 
Francisella tularensis
 
 is a small Gram-negative facultative in-
tracellular bacterium, and the causative agent of an acute
febrile illness known as tularemia (1). This highly virulent
pathogen, which can be transmitted via aerosol, has been
classified as a Category A bioterrorism agent (2). The atten-
uated live vaccine strain (LVS)
 
*
 
 of 
 
F. tularensis
 
 was derived
by repeated passage of a virulent strain on agar (3). How-
ever, the efficacy and safety of this vaccine remains poorly
defined, and it is not licensed for use in humans in the
United States today. Thus, there is an interest in the devel-
opment of a new 
 
F. tularensis
 
 vaccine, as well as the identi-
fication of correlates of protection for tularemia infection
that can be used during testing of vaccine candidates.
Murine infection with LVS is a well-established and
convenient model for characterizing the mechanisms of
protection against tularemia infection, as well as for other
intracellular bacteria in general (4, 5). Although 
 
F. tularensis
 
LVS is avirulent for humans, it is highly virulent for labora-
tory mice, and when administered i.p. causes a fulminent
infection in these animals that is histopathologically similar
to human tularemia (1, 4, 6). In the mouse model, the out-
come of a primary LVS infection is dependent on the route
of inoculation: the 50% lethal dose (LD
 
50
 
) when infection
 
is initiated via the intradermal (i.d.) route is 
 
 
 
10
 
6
 
 bacteria
in BALB/cByJ mice, whereas infection via the i.v. or i.p.
routes has an LD
 
50
 
 that approaches a single bacterium (6,
7). Mice given a sublethal LVS infection via the i.d. route
are solidly immune to a secondary i.p. challenge of as much
as 100,000 LD
 
50
 
s. In both mice and humans, survival and
resolution of a primary 
 
Francisella
 
 infection confers a long-
lasting specific protective immunity to reinfection (1, 4, 6).
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Abbreviations used in this paper:
 
 BMMØ, bone marrow derived macro-
phage(s); cDMEM, complete DMEM; i.d., intradermal; LVS, live vaccine
strain.T
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IFN-independent Control of 
 
Francisella
 
 Infection by T Cells
 
Mice genetically deficient for IFN-
 
 
 
, as well as mice
treated with neutralizing anti–IFN-
 
 
 
 antibodies, quickly
succumb to a primary LVS infection with doses that are
sublethal for normal mice (8). However, studies investigat-
ing the role of IFN-
 
 
 
 during a secondary LVS infection
suggest that IFN-
 
 
 
 may be less critical for survival during a
secondary LVS challenge. Treatment of LVS-infected mice
with neutralizing antibodies to IFN-
 
 
 
 had no detectable ef-
fect on the outcome of a secondary i.p. challenge (8) or on
a secondary i.d. challenge (9) except at high i.d. challenge
doses. Thus, there appear to be immune mechanisms that
function during a late primary and a secondary immune re-
sponse to LVS that do not require IFN-
 
 
 
.
Here we investigate mechanisms that control LVS intra-
cellular growth in the absence of signaling through the
macrophage IFN-
 
 
 
 receptor. To this end, we measured
the ability of different LVS-immune splenic T cell subsets
to control LVS intracellular growth in either wild-type
(10) or IFN-
 
 
 
 receptor deficient (IFN
 
 
 
R KO) bone mar-
row macrophages (BMMØs). Surprisingly, LVS-immune
spleen cells inhibited LVS intracellular growth by as much
as 95% in the IFN
 
 
 
R KO BMMØ monolayer. CD4
 
 
 
cells, and to a greater extent CD8
 
 
 
 T cells, controlled LVS
intracellular growth in both wild-type and IFN
 
 
 
R KO
BMMØs. Further, a unique population of Thy1
 
 
 
CD4
 
 
 
CD8
 
 
 
 cells that was previously suggested to be operative
during secondary immunity to LVS in vivo (11, 12)
strongly controlled LVS intracellular growth in vitro. In
the absence of IFN-
 
 
 
 stimulation of macrophages, these T
cell subsets relied to varying extents upon TNF-
 
 
 
 produc-
tion to inhibit LVS intracellular growth.
 
Materials and Methods
 
Animals.
 
6–8-wk-old male specific-pathogen-free 129S1/
SvlmJ or IFN
 
 
 
R-deficient mice on a 129S1/SvlmJ background were
purchased from The Jackson Laboratory. Animals were housed in
sterile microisolator cages in barrier environment at the Center for
Biologics Evaluation and Research. Mice were fed autoclaved
food and water ad libitum. All experiments were performed under
Institutional Animal Care and Use Committee guidelines.
 
Culture and Infection of BMMØ with Bacteria.
 
BMMØ were used
as the target cells for the in vitro system. BMMØ were cultured as
described previously (10). Bone marrow was flushed from femurs
of healthy IFN
 
 
 
R-deficient or wild-type mice with DMEM
(Life Technologies) supplemented with 10% heat-inactivated
FCS (HyClone), 10% L-929 conditioned medium, 0.2 mM
 
l
 
-glutamine (Life Technologies), 1 mM HEPES buffer (Life
Technologies), and 0.1 mM nonessential amino acids (Life Tech-
nologies; complete DMEM [cDMEM]). Cells were washed, a
single cell suspension prepared, and cells plated at 2 
 
 
 
 10
 
6
 
 in 24-
well plates (Costar) or at 10
 
6
 
 in 48-well plates, in cDMEM sup-
plemented with 50 
 
 
 
g/ml gentamycin (Life Technologies) and
incubated at 37
 
 
 
C in 5% CO
 
2
 
. After 1 d of incubation, the me-
dium was replaced with antibiotic-free cDMEM, and the cells
were incubated for an additional 6 d at 37
 
 
 
C in 5% CO
 
2
 
. The
medium was replaced with fresh, gentamycin-free cDMEM ev-
ery 2 d during the 7-d incubation.
After the 7-d culture period, the BMMØ formed a confluent
monolayer, and the concentration of BMMØ was estimated to be
 
10
 
7
 
 cells/well in the 24-well plates and 5 
 
 
 
 10
 
6
 
 cells/well in the
48-well plates (10). BMMØ were then infected with 
 
F. tularensis
 
LVS according to the following protocol: bacteria were diluted
from frozen stocks in cDMEM and added at a multiplicity of in-
fection (MOI) of 1:20–1:40 (bacterium-to-BMMØ ratio). A
low MOI was chosen to permit controlled infection of the mac-
rophage monolayer over 3 to 5 d, permitting time for lympho-
cyte–macrophage interactions and modeling in vivo relationships.
LVS was coincubated with BMMØ at 37
 
 
 
C in 5% CO
 
2
 
 for 2 h
and then washed three times with PBS (Life Technologies). The
monolayers were then incubated for 45 min–1 h in cDMEM sup-
plemented with 50 
 
 
 
g/ml gentamicin to eliminate extracellular
bacteria. The BMMØ were then washed a further three times
with PBS. After the last wash, PBS was replaced with 1 ml/well
cDMEM and the cells were incubated at 37
 
 
 
C in 5% CO
 
2
 
 for the
remainder of the experiment. To determine bacterial uptake,
some BMMØs were lysed with sterile distilled water for 3 min
immediately after washing with PBS. Culture lysates were serially
diluted in PBS and plated on Mueller Hinton agar plates. The
plates were incubated for 2–3 d at 37
 
 
 
C in 5% CO
 
2
 
, and LVS col-
onies were counted. Growth of LVS in BMMØ was monitored
by lysing cultures at the indicated time points, plating lysates, and
counting LVS colonies as described above.
 
Infection of Mice with LVS and Listeria monocytogenes EGD.
 
Wild-type mice were infected i.d. with 10
 
4
 
 LVS or 
 
L. monocytoge-
nes
 
 strain EGD (ATCC 15313). These concentrations of bacteria
were chosen to establish a sublethal infection that is cleared from
organs by 2 to 3 wk and that engenders long-term protective im-
munity to a lethal secondary infection; such mice were therefore
used as a source of LVS-primed or 
 
Listeria
 
-primed splenocytes.
 
Harvesting and Enrichment of Splenocytes, and Assay for Control of
Intracellular LVS Growth.
 
Spleens were aseptically removed from
selected mice and disrupted with a 3-ml syringe plunger. A single-
cell suspension was prepared, and erythrocytes were lysed with
ammonium chloride. Cells were washed, viability was assessed by
exclusion of trypan blue, and cells were resuspended in Dulbecco
PBS-2% FCS to the appropriate concentration. In most experi-
ments, wild-type macrophages in the spleen were depleted by ad-
herence; spleen cells in cDMEM were added to 75 cm
 
2
 
 tissue cul-
ture flasks for 2 h at 37
 
 
 
C and nonadherent cells recovered by
gentle pipetting. The recovered nonadherent splenocytes were
added to BMMØs cultures at various concentrations as indicated.
Unless otherwise stated, 5 
 
 
 
 10
 
6
 
 splenocytes were added to each
well in the 24-well plate cultures, and 2.5 
 
 
 
 10
 
6
 
 splenocytes were
added to the 48 well cultures (
 
 
 
1 splenocyte to 2 BMMØs).
Depletion of various lymphocyte subsets before their addition
to the in vitro system was achieved by performing in vivo deple-
tion of the desired cell type before harvesting of the splenocytes
(11). On days 
 
 
 
3 and 
 
 
 
1 before harvest, mice were given either
500 
 
 
 
g of anti-CD4 mAb (clone GK1.5), 300 
 
 
 
g anti-CD8 mAb
(clone 2.43), or 500 
 
 
 
g of anti-Thy1.2 mAb (clone 30-H12) via
the i.p. route. Cell depletions routinely reduced the depleted cell
type to less than 1% of the total cell population. In all cases, start-
ing and depleted splenocyte populations were analyzed by flow
cytometry as described below.
To obtain separated and purified cell populations for the in
vitro assay, CD4
 
 
 
 T cells, CD8
 
 
 
 T cells, and Thy1
 
 
 
CD4
 
 
 
CD8
 
 
 
populations were enriched using CD4
 
 
 
 cell, CD8
 
 
 
 cell, and
Thy1.2
 
 
 
 cell enrichment columns (MACS magnetic cell sorting
system; Miltenyi Biotec) according to the manufacturer’s instruc-
tions. To obtain the Thy1
 
 
 
CD4
 
 
 
CD8
 
 
 
 splenocyte population,
mice were depleted in vivo of CD4
 
 
 
 and CD8
 
 
 
 T cells before
harvesting of the spleens, and then these spleens were depleted ofT
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B220
 
 
 
 B cells using a B220
 
 
 
 MACS cell depletion column. The
remaining Thy1
 
 
 
 cell population was obtained using a Thy1.2
 
 
 
MACS cell enrichment column; these cells were 
 
 
 
2% of total
splenocytes. Cell populations were routinely greater than 90% of
the desired population using this method of enrichment. In all
cases, starting and enriched splenocyte populations were analyzed
by flow cytometry using a fluorescence-activated cell sorter scan
as described below.
In some experiments, TNF-
 
 
 
 was neutralized in the culture by
addition of a pair of azide-free, low-endotoxin mouse anti–TNF-
 
 
 
neutralizing antibodies (MP6-XT3 and G281–2626; BD Bio-
sciences) at a concentration of 20 
 
 
 
g/ml. In other experiments, 1
mM N-monomethyl-
 
l
 
-arginine (NMMA; Sigma-Aldrich) was
added to inhibit synthesis of nitric oxide in the cultures. Antibod-
ies and NMMA were added to the cocultures with splenocytes at
the initiation of the culture period.
 
Quantitation of Cytokines and NO in BMMØ Culture Superna-
tants. Culture supernatants were assayed for IFN- , IL-12p40,
and TNF-  by standard sandwich ELISAs. All antibody pairs and
standards were purchased from BD Biosciences, and all ELISAs
performed in accordance with the manufacturer’s instructions.
Samples were read at 405 nm on a VersaMax tunable microplate
reader with a reference wavelength of 630nm (Molecular De-
vices). Cytokines were quantified by comparison to recombinant
standards (all purchased from BD Biosciences) using four-parame-
ter fit regression in the SoftMax Pro ELISA analysis software
(Molecular Devices).
Nitric oxide (NO) was detected in culture supernatants by the
Griess reaction (13). Briefly, 100  l aliquots of culture superna-
tants were incubated with an equal volume of commercial Griess
reagent (Sigma-Aldrich) for 5 min at room temperature, and the
absorbance of each sample at 490 nm was measured. NO2 was
quantified by comparison to serially diluted NaNO2 as a standard
using four-parameter fit regression in the SoftMax Pro ELISA
analysis software (Molecular Devices).
Analysis of Splenocyte Populations Using Flow Cytometry. Cells
were prepared as described above and stained for B220 , CD4 ,
CD8 , Thy1.2 , CD11b , and DX5  cell surface markers as de-
scribed previously (10, 11). Briefly, single cell suspensions were
mixed with anti-CD16 (Fc Block; BD Biosciences) for 10 min on
ice. FITC-conjugated rat IgG2a, PE-conjugated rat IgG2b, and
allophycocyanin (APC)-conjugated rat IgG2a were used as iso-
type controls. FITC-conjugated anti-CD45/B220 (RA3–6B2),
PE-conjugated anti-CD4 (RM4–4), PE-conjugated anti-CD8a
(53–6.7), PE-conjugated anti-CD11b (M1/70), PE-conjugated
anti-DX5 (DX5), or APC-conjugated anti-CD90/Thy1.2 (53–
2.1) monoclonal antibody was added, and cells were incubated
for an additional 30 min on ice. All antibodies were obtained
from BD Biosciences, and optimal concentrations for staining
were determined in separate experiments. Cells were washed
three times in PBS-2% FCS, fixed in 0.5% buffered paraformalde-
hyde, and analyzed using a BD Biosciences LSR flow cytometer
with gates set to viable lymphocytes and monocytes according to
forward and side-scatter profiles. Among the total population of
splenocytes, 129S1/SvlmJ mice had  25–30% CD4  cells, 11–
15% CD8  cells, 40% B220  cells, 15% CD11b  cells, and 2%
DX5  cells.
Results
Growth Inhibition of LVS in Wild-Type and IFN R-defi-
cient BMMØ. We tested the ability of LVS-immune
splenocytes from wild-type mice to control the intracellu-
lar growth of LVS in BMMØs derived from both wild-
type and IFN R KO mice. Splenocytes were obtained
from LVS-immune wild type mice that were infected
(primed) 4 wk earlier with a sublethal in vivo LVS infec-
tion. To minimize the influence of wild-type macro-
phages in the splenocyte population, adherent cells in the
spleen were depleted by plastic adherence before addition
to the BMMØ cultures. Nonadherent immune spleno-
cytes were cocultured with LVS-infected wild-type and
IFN R KO BMMØ monolayers. Because previous ex-
periments demonstrated that the maximal control of LVS
growth in BMMØ by immune splenocytes occurred after
72 h of coculture (10), here we used the 72 h time point
to compare the ability of splenocytes to control LVS
growth in the two different BMMØ monolayers. As seen
in Fig. 1, addition of LVS-immune, but not naive, spleno-
cytes to both types of infected BMMØ monolayers re-
sulted in readily measurable and significant (P   0.01) in-
hibition of LVS growth compared with LVS growth in
cultures containing either naive splenocytes or no spleno-
cytes. LVS replicated to a similar extent in both the wild-
type and IFN R KO BMMØs, and growth was not sig-
nificantly affected by the addition of naive splenocytes to
the cultures. Coculture of LVS-immune splenocytes with
wild-type BMMØs resulted in a 3.5 log10 reduction in
growth of the bacteria, while coculture with the IFN R
KO BMMØs resulted in a 1.6 log10 reduction of LVS
growth. Thus, as expected, a substantial fraction of the
control of LVS growth was mediated by IFN-  stim-
ulation of infected macrophages. Nonetheless, in multi-
ple replicate experiments, control of LVS growth in the
IFN R KO BMMØs by wild-type immune splenocytes
ranged from a 1 to 1.7 log10 reduction. In absolute num-
bers, this represents inhibition of more than 95% of LVS
growth in the IFN R KO BMMØs by LVS-immune
wild-type splenocytes.
To determine whether the observed control of LVS in-
tracellular growth in the IFN R KO BMMØs is a specific
event, we tested the ability of splenocytes harvested from
mice infected with another intracellular pathogen, Listeria
monocytogenes EGD, to control LVS intracellular growth. As
shown in Fig. 2, A and B, splenocytes from LVS-immune
mice controlled LVS growth in both sets of BMMØ
monolayers. However, neither Listeria-immune nor naive
splenocytes had a significant (P   0.01) effect on control of
LVS growth in the wild-type and IFN R KO BMMØ
monolayers. These results indicate that the control of LVS
growth in the IFN R KO BMMØs is specific.
TNF-  and NO Contribute to LVS Growth Inhibition in the
IFN R KO BMMØs. We next examined the mecha-
nisms used by the LVS-immune splenocytes to control
LVS growth in the IFN R KO BMMØs. As TNF-  ap-
pears to be important for survival of both a primary and
secondary LVS infection (8, 9), we tested the impact of ab-
rogation of TNF-  activity on the control of LVS growth
in the culture system. As seen in Fig. 3, A and B, inhibition
of TNF-  activity by addition of neutralizing anti–TNF- 
Abs to the cultures significantly reversed the ability of theT
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382 IFN-independent Control of Francisella Infection by T Cells
splenocytes to control LVS growth in both the IFN R KO
and wild-type BMMØ monolayers (P   0.01 compared
with cultures with control IgG or no antibodies). The
IFN R KO BMMØ cultures that were treated with anti–
TNF-  Ab exhibited no significant control of intracellular
LVS growth compared with that seen with naive cells (P  
0.01), while the wild-type cultures treated with anti–TNF- 
Ab retained significant control compared with that seen
with naive cells (P   0.01).
It has previously been shown that LVS-infected murine
macrophages treated in vitro with recombinant IFN-  use
NO as a primary mechanism for controlling LVS intracel-
lular growth, and that this NO production is partially de-
pendent on the autocrine action of macrophage TNF- 
(14, 15). Thus, we next investigated the possibility that the
role of TNF-  in our IFN R KO BMMØ cocultures was
to induce macrophage production of NO independently of
IFN-  stimulation of macrophages. As seen in Fig. 3, A
Figure 2. Specificity of control of
LVS growth in (A) wild-type BMMØ
and (B) IFN R KO BMMØs. Infected
BMMØs were cocultured with wild-
type splenocytes from either uninfected
mice (naive spleen), mice infected intra-
dermally 4 wk previously with LVS
(LVS primed spleen), or with L. monocy-
togenes (Listeria primed spleen). Immedi-
ately following LVS infection of the
BMMØs, splenocytes were added to the
indicated wells at a ratio of 1:2 (spleno-
cyte:BMMØ). 72 h after infection, the
BMMØ were assessed for levels of intra-
cellular bacteria as described in the leg-
end to Fig. 1. Values shown are the
mean numbers of CFU/ml   the SEM
of viable bacteria (triplicate samples).
Asterisks (*) indicate P values  0.01 as
compared with cocultures containing
naive spleen cells. These results are
representative of three experiments of
similar design.
Figure 1. Control of LVS growth by
wild-type LVS-immune splenocytes in (A)
wild-type BMMØ and (B) BMMØ that
lack the IFN R. BMMØ from wild-type
and IFN R KO mice were infected with
LVS at an MOI of 1:40 (bacterium-to-
macrophage ratio). Infected BMMØs were
cocultured with splenocytes from either
uninfected mice (naive spleen), mice in-
fected intradermally with LVS 4 wk previ-
ously (primed spleen), or no spleen cells
(macrophages    LVS). Immediately after
LVS infection of the BMMØs, splenocytes
were added to the indicated wells at a ratio
of 1:2 (splenocyte:BMMØ). 72 h after in-
fection, the BMMØ were washed, lysed,
and plated to determine the levels of intra-
cellular bacteria. Values shown are the mean
numbers of CFU/ml   the SEM of viable
bacteria (triplicate samples). Asterisks (*) in-
dicate P values  0.01 as compared with
cocultures containing naive spleen cells.
These data are representative of five experi-
ments of similar design.T
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and B, addition of the nitric oxide synthase inhibitor
NMMA significantly reversed splenocyte control of LVS
growth in both the IFN R KO and wild-type BMMØ
monolayers compared with untreated control cultures (P  
0.01). This reversal was comparable in magnitude to that
seen with anti–TNF-  Ab treatment.
Depletion and Enrichment of Spleen Cell Subsets Reveals
Roles for CD8  T Cells as well as for Unique Thy1 CD4 
CD8  Cells in Control of LVS Intracellular Growth in the Ab-
sence of IFN- . We next sought to determine the T cell
subpopulations required to control LVS intracellular
growth in both wild-type and IFN R KO BMMØ mono-
layers. As our previous experiments revealed that growth
inhibition of LVS in the wild-type and IFN R KO
BMMØ monolayers was specific, and as survival of an LVS
infection is dependent upon specific     T cells (10–12,
16, 17), we depleted mice in vivo of various T cell subsets
before addition of their splenocytes to the in vitro culture
system. Mice were depleted of total Thy1  cells, CD4 
cells, CD8  cells, or both CD4  and CD8  cells simulta-
neously. The splenocytes that remained following deple-
tion were then added to the BMMØ cultures, and LVS
growth was determined after 72 h of coculture. As shown
in Fig. 4, A and B, splenocytes obtained from LVS-
immune mice depleted of CD4  cells, CD8  cells, or CD4 
and CD8  cells simultaneously, all controlled LVS intracel-
lular growth in both wild-type and IFN R KO BMMØs
in a manner similar to whole primed splenocytes. In con-
trast, splenocytes obtained from LVS-immune mice de-
pleted of Thy1  cells exhibited a dramatic and significant
(P   0.01) reversal of control of growth when cocultured
with both types of BMMØs (Fig. 4, A and B). In some ex-
periments, depletion of Thy1  cells resulted in a popula-
tion that did not significantly control intracellular LVS
growth as compared with naive cells. These results indicate
that a Thy1 CD4 CD8  cell population is involved in
control of LVS intracellular growth.
To further define the T cell subsets responsible for con-
trol of LVS intracellular growth, we positively selected
CD4  T cells, CD8  T cells, and Thy1 CD4 CD8  cells
from LVS-immune mouse splenocytes (see Materials and
Methods). The purified T cell subpopulations were co-
cultured with LVS-infected wild-type and IFN R KO
BMMØs. All cell populations were added in equivalent num-
bers to the BMMØ monolayer (1:2 ratio of splenocyte:
BMMØ). As shown in Fig. 5 A, purified CD4  T cells,
CD8  T cells, and Thy1 CD4 CD8  T cells were all ca-
pable of controlling LVS growth in wild-type BMMØs,
and to an even greater extent than whole primed spleno-
cytes. All of these LVS-immune T cell subpopulations re-
duced LVS numbers in wild-type macrophages signifi-
cantly, by over 99% as compared with naive splenocytes
(P   0.01 compared with naive cells).
All three T cell subsets also controlled LVS growth in
IFN R KO BMMØs as compared with naive splenocytes
(P    0.001; Fig. 5 B). However, the control of LVS
growth in IFN R KO BMMØs clearly varied in magni-
tude with the different T cell subsets. Repeated experi-
ments consistently found that CD4  T cells were the least
effective T cell subset at mediating growth inhibition of
LVS in macrophages that cannot respond to IFN- , while
CD8  T cells and Thy1 CD4 CD8  T cells were consis-
Figure 3. Effects of TNF-  neutral-
ization and iNOS inhibition on control
of LVS growth in (A) wild-type
BMMØ and (B) IFN R KO BMMØs.
Infected BMMØs were cocultured with
splenocytes from either uninfected mice
(naive spleen), or wild-type mice in-
fected intradermally with LVS 4 wk pre-
viously (primed spleen). Immediately
following LVS infection of the BMMØs,
splenocytes were added to the indicated
wells at a ratio of 1:2 (splenocyte:
BMMØ). In the indicated cultures, ei-
ther anti–TNF-  Abs or control IgG Ab
(20   g/ml), or 1 mM NMMA, were
added to the cultures at the time of ad-
dition of the splenocytes. 72 h after in-
fection, the BMMØ were assessed for
levels of intracellular bacteria as de-
scribed in the legend to Fig. 1. Values
shown are the mean numbers of CFU/
ml   the SEM of viable bacteria (tripli-
cate samples). Asterisks (*) indicate P
values  0.01 as compared with cocul-
tures containing naive spleen cells.
These results are representative of three
experiments of similar design.T
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tently more effective and comparable to each other (see
Fig. 7).
The phenotype of purified Thy1 CD4 CD8  was exam-
ined in detail by flow cytometry for the expression of other
cell surface markers. These cells were largely positive for
   T cell receptors ( 98%) and CD3 ( 85%), but mostly
negative for B220 ( 3%), DX5 ( 3%), CD11b (7.5%),
and    T cell receptors ( 3%). Determination of NK1.1
staining was not possible, as mice of the 129 background
lack the NK1.1 marker.
To study the mechanisms by which these three T cell
subsets contribute to control of LVS growth in the wild-
type and IFN R KO BMMØ cultures, secretion of cyto-
kines and NO into the coculture supernatants was exam-
ined. As shown in Fig. 6 A, supernatants from wild-type
BMMØ cultures containing infected macrophages alone or
naive splenocytes had undetectable levels of IFN- . In
contrast, cultures containing whole primed splenocytes,
purified CD4  cells, CD8  cells, or Thy1 CD4 CD8 
cells, all produced IFN-  (Fig. 6 A). However, while cul-
tures containing whole primed spleen cells and purified
CD4  cells produced high quantities of IFN- , cultures
containing wild-type BMMØs and purified CD8  cells or
Thy1 CD4 CD8  cells produced relatively low levels of
IFN- . The levels of IFN-  were consistently found to be
several-fold higher in the cultures containing IFN R KO
BMMØs, likely as a result of the inability of the macro-
phages in those cultures to utilize and remove the IFN- 
from the cultures. This is particularly notable for the CD8 
T cells. Interestingly, however, it appears that the Thy1 CD4 
CD8  cells produce less net IFN-  than the CD4  and
CD8  cells (Fig. 6 A).
Similarly, TNF-  production was found to be very low
in both the wild-type and IFN R KO BMMØ cultures
containing either LVS-infected macrophages alone or plus
naive splenocytes, and was significantly increased upon ad-
dition of LVS-immune whole splenocytes or each of the
three T cell subsets (Fig. 6 B). The IFN R KO BMMØ
cultures exhibited lower levels of TNF-  as compared with
the wild-type BMMØ cultures. In contrast, IL-12 produc-
tion was similar in both the wild-types and IFN R KO
BMMØ cultures (Fig. 6 C); small amounts of IL-12 were
evident in cultures containing naive splenocytes, and these
amounts increased substantially upon addition of either
whole primed splenocytes, CD4  cells, CD8  cells, or
Thy1 CD4 CD8  cells.
The secretion of NO by macrophages in the cultures was
examined and found to correlate most obviously with
TNF-  production (Fig. 6 D). NO was undetectable in
both the wild-type and IFN R KO BMMØ cultures con-
taining naive splenocytes, and significantly increased upon
addition of LVS-immune whole splenocytes, as well as
each of the three T cell subsets. The IFN R KO BMMØ
cultures exhibited lower levels of NO as compared with
the wild-type BMMØ cultures. Overall, NO production
most closely paralleled TNF-  production.
CD4 , CD8 , and Thy1 CD4 CD8  Cells All Utilize
TNF-  to Mediate Inhibition of LVS Intracellular Growth in
Both Wild-Type and IFN R KO BMMØs. As TNF-  was
found to be a key cytokine that contributes to inhibi-
tion of LVS growth in both wild-type and IFN R KO
BMMØs by whole primed splenocytes (Fig. 3), we next
investigated the effect of TNF-  neutralization on the abil-
ity of the three different T cell subsets to control LVS
growth. As seen in Fig. 7, A and B, inhibition of TNF- 
Figure 4. Effects of T cell depletion on control of LVS growth in (A)
wild-type BMMØ and (B) IFN R KO BMMØs. Infected BMMØs
were cocultured with splenocytes obtained from either uninfected mice
(naive spleen), wild-type mice infected intradermally with LVS 4 wk pre-
viously (primed spleen), or LVS-primed wild-type mice that had been in
vivo depleted of the indicated T cell subsets by intraperitoneal injection
with Abs specific for CD4, CD8, CD4 and CD8 simultaneously, or
Thy1.2 cell surface markers. Immediately after LVS infection of the
BMMØs, splenocytes were added to the indicated wells at a ratio of 1:2
(splenocyte:BMMØ). 72 h after infection, the BMMØ were assessed for
levels of intracellular bacteria as described in the legend to Fig. 1. Values
shown are the mean numbers of CFU/ml   the SEM of viable bacteria
(triplicate samples). Asterisks (*) indicate P values  0.01 as compared
with cocultures containing naive spleen cells. These results are representa-
tive of three experiments of similar design.T
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activity by addition of neutralizing anti–TNF-  Abs to the
cultures significantly (P   0.01) reversed the ability of all
three T cell subsets to control LVS growth in both the
IFN R KO and wild-type BMMØ monolayers as compared
with control cocultures. In repeated experiments, CD4 
and CD8  T cells were consistently affected more strongly
by neutralization of TNF-  in the IFN R KO BMMØ
cultures than were Thy1 CD4 CD8  T cells. Thus, LVS
growth inhibition mediated by either CD4  T cells or
CD8  T cells in the IFN R KO BMMØ cocultures was
completely reversed by treatment with anti–TNF-  Ab,
and was not significantly different from that of naive sple-
nocytes (P   0.01). In contrast, IFN R KO BMMO co-
cultures with Thy1 CD4 CD8  cells that were treated
with anti–TNF-  Ab still exhibited a significant 88% re-
duction of LVS numbers as compared with naive spleen
cell cultures (P   0.01). Therefore, growth inhibition by
Thy1 CD4 CD8  T cells is mediated by IFN- , TNF- ,
and other mechanisms that remain to be identified.
Discussion
Development of vaccines for intracellular pathogens such
as Mycobacterium tuberculosis, a global public health problem,
and Francisella tularensis, a potential bioterrorism pathogen,
is limited by difficulties in conducting field trials, lack of
correlates of protection, and a generally incomplete under-
standing of mechanisms of protective immunity. Although
IFN-  is often proposed as a correlate, the available evi-
dence suggests that production of IFN-  is likely to be
necessary but not sufficient for successful protection against
intracellular bacteria (18). Thus, correlates of protection
can best be determined by expanding our understanding of
the components of the immune system that are involved in
limiting intracellular growth of these pathogens. To this
end, we have previously developed an in vitro model sys-
tem to evaluate the cell types, cytokines, and receptors in-
volved in inhibition of F. tularensis growth inside its pri-
mary host cell, the macrophage (10). Here we have applied
this in vitro system to examine the T cell subsets responsi-
ble for F. tularensis LVS growth inhibition in the absence of
IFN-  stimulation of the macrophage.
Using IFN R KO BMMØs, we showed that as much as
95% of LVS intracellular growth can specifically be inhibited
in macrophages that cannot respond to IFN-  (Figs. 1 B and
2). Further, we demonstrated that both CD4  T cells and
especially CD8  T cells are capable of inhibiting LVS intra-
cellular growth in the absence of IFN   stimulation of the
macrophage (Figs. 4 and 5). Consistent with the well-
known importance of CD4  T cells as sources of IFN- ,
CD4  T cells were notably less efficient than CD8  T cells
at inhibiting LVS growth in IFN R KO BMMØs. Surpris-
ingly, we also identified an unusual T cell subset that
strongly controlled LVS intracellular growth in both wild-
type and IFN R KO BMMØs: the double negative
(CD4 /CD8 ) Thy1  T cell (Fig. 5). The ability of all three
T cell subsets to inhibit LVS intracellular growth in the
IFN R KO BMMØs depended upon TNF-  production to
varying extents (Figs. 3 and 7 B). While much of the intra-
cellular growth control in vitro by CD4  and CD8  T cells
could be attributed to the combination of IFN-  and TNF- ,
it appears that yet another (to be identified) mechanism(s) is
operative with the double negative Thy1.2  T cells.
In many intracellular infections, IFN-  is considered a
primary candidate as a correlate of protection. This is
largely due to its pivotal role in activating macrophages, as
Figure 5. Ability of various T cell subsets to
control LVS growth in (A) wild-type BMMØ
and (B) IFN R KO BMMØs. Infected BMMØs
were cocultured with splenocytes obtained
from either uninfected mice (naive spleen),
whole primed splenocytes from immune wild-
type mice (primed spleen), or various T cell
subsets enriched from immune wild-type mice
(CD4  cells, CD8  cells, and Thy1 CD4 CD8 
cells). All splenocyte populations were added at
a 1:2 ratio (splenocyte to BMMØ). 72 h after
infection, the BMMØ were assessed for levels
of intracellular bacteria as described in the leg-
end to Fig. 1. Values shown are the mean num-
bers of CFU/ml   the SEM of viable bacteria
(triplicate samples). Asterisks (*) indicate P values
 0.01 as compared with cocultures containing
naive spleen cells. These results are representa-
tive of three experiments of similar design.T
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well as the extreme sensitivity of IFN- –deficient mice and
humans to many intracellular pathogens. Indeed, studies
using the F. tularensis LVS murine infection model have
also underscored the importance of IFN-  for the success-
ful development and survival of primary infections with
this intracellular bacterium. Mice deficient in T cells sur-
vive more than a month after a primary i.d. LVS infection,
but then succumb (11, 16, 17). The early T cell–indepen-
dent phase of immunity is dependent upon both IFN- 
and TNF-  production, but the final resolution and clear-
ance of LVS infection is clearly dependent upon     T
cells (8, 16). The large amounts of IFN   produced during
the T cell–independent phase of infection are obviously in-
sufficient to resolve the infection, and thus another T cell
function must be necessary to mediate clearance.
The role of IFN-  in secondary intracellular infections,
which is relevant to the case of vaccination and secondary
challenge, has not been thoroughly studied, but there are a
few pertinent examples. IFN- –deficient (GKO) mice
primed with an attenuated L. monocytogenes mutant strain
were fully protected against secondary lethal challenge
with virulent L. monocytogenes (19). Protection was medi-
ated largely by CD8  T cells, and included production of
TNF-  and perforin (20, 21). We have recently demon-
strated that IFN- –independent immunity to secondary
challenge, mediated primarily by CD4  T cells, also exists
in the Mycobacterium tuberculosis murine infection model
(unpublished data). In the studies presented here, much of
the immunity to LVS observed in vitro using IFN R KO
BMMØs also relied largely upon TNF- , but was medi-
ated by multiple T cell subsets. The few other studies that
have examined this topic in Francisella infection further
suggest that IFN-  may have relatively less importance
during late primary and secondary LVS infections than in
Figure 6. Secretion of cytokines and NO
into culture supernatants after coculture of
LVS infected BMMØs and immune spleno-
cytes. Wild-type (black bars) and IFN R
KO (gray bars) BMMØ were infected with
LVS and cocultured with the indicated sple-
nocyte populations. Splenocytes from either
unprimed mice or mice infected 4 wk pre-
viously with an intradermal LVS infection
were cocultured with LVS-infected mac-
rophages at a 1:2 ratio (splenocytes to
BMMØ). Similarly, CD4  and CD8  and
Thy1 CD4 CD8  splenocyte subpopula-
tions were added to infected BMMØ cul-
tures at a 1:2 ratio. Culture supernatants
were collected 72 h later and tested for
IFN-  (A), TNF-  (B), IL-12 (C), and NO
(D). Values shown are the mean ng/ml  
the SEM of the indicated cytokine (A–C) or
mean   M/ml nitrite (D) (triplicate sam-
ples). These results are representative of
three experiments of similar design.T
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early primary infection. For example, Leiby et al. (8) found
that mice treated with neutralizing anti–IFN-  mAbs did
not survive primary sublethal LVS infection if the mAbs
were administered within the first 2–3 d of infection, but
survived if anti–IFN-  was administered at later times.
Further, treatment with neutralizing anti–IFN-  mAbs
during a secondary lethal i.p. challenge had no detectable
effect on survival (8). Similarly, Sjöstedt et al. (9) found
that treatment with neutralizing anti–IFN-  mAbs during
secondary lethal i.d. challenge only reduced survival of the
animals when the challenge inoculum was extremely high.
Collectively, these data indicate that very significant IFN-
 –independent mechanisms of immunity exist in multiple
infection models, and may be mediated by a variety of dif-
ferent T cell subsets.
In contrast to depletion of IFN- , in vivo depletion of
TNF-  during secondary i.d. LVS challenge resulted in loss
of control of infection and death at all challenge doses (9).
Similarly, here blockade of TNF-  activity by addition of
neutralizing anti–TNF-  antibodies reduced the control of
intracellular LVS growth in wild-type macrophages, and
largely ablated it in IFN R KO macrophages (Fig. 3 B).
The exact cellular source and form of this TNF- , as well
as the receptors used, remain to be determined in future
experiments, but the data to date suggest that it is likely to
be T cell derived rather than macrophage derived. The
form may be suggested by studies that take advantage of
transgenic mice that express membrane TNF-  but do not
secrete soluble TNF-  (22). Intriguingly, Mycobacteria in-
fection of such memTNF transgenic mice progresses simi-
larly to that in wild-type mice (23), even though mice
lacking all TNF-  are acutely susceptible to Mycobacteria
infections (24, 25). Preliminary results similarly suggest
that transgenic memTNF-  mice, unlike TNF- –deficient
mice, also survive primary i.d. LVS infection (unpublished
data). Thus, we propose that membrane TNF-  expressed
on LVS-specific T cells is (at least in part) responsible for
IFN- –independent control of LVS infection, and are ac-
tively pursuing studies to address this hypothesis.
Surprisingly, depletion experiments as well as positive se-
lection of T cell subsets led us to an unexpected T cell sub-
set that has a powerful capacity to control LVS growth in
macrophages. These cells were CD4 CD8 B220 , and
   Thy1.2 CD3 , and used IFN- , TNF- , and another
unidentified mechanism to mediate LVS growth inhibition
(Fig. 7, A and B). To the best of our knowledge, these data
are the first direct demonstration of growth inhibition of an
intracellular pathogen by an   TCR  double negative T
cell. The relationship of these cells to other double negative
T cells that have been previously described remains to be
clarified, but the available data suggest that these may be
novel subset. Cells with a similar phenotype, although rare
in murine splenocytes, have been previous recognized in
autoimmune mice, but are usually NK1.1 , B220 , and
have a restricted T cell receptor repertoire (26, 27). Be-
cause the 129 mouse strain used here (due to the availabil-
ity of IFN R KO mice on this background) does not ex-
press the NK1.1 allele, we cannot directly examine this
marker. However, the overwhelming majority of the cells
we describe here do not express B220 or another natural
killer cell marker, DX5. Other double negative T cells that
have been described include CD1-restricted T cells that
Figure 7. Effects of TNF-  neutralization on the ability of different T
cell subsets to control LVS growth in (A) wild-type BMMØ and (B)
IFN R KO BMMØs. Infected BMMØs were cocultured with spleno-
cytes obtained from either uninfected mice (naive spleen), whole primed
splenocytes from immune wild-type mice (primed spleen), or various T
cell subsets enriched from immune wild-type mice (CD4  cells, CD8 
cells, and CD4 CD8 Thy1.2  cells). All splenocyte populations were
added at a 1:2 ratio (splenocyte to BMMØ). Anti–TNF-  Abs were
added to the wells at the time of addition of the splenocytes to the in-
fected BMMØs. 72 h after infection, the BMMØ were assessed for levels
of intracellular bacteria as described in the legend to Fig. 1. Values shown
are the mean numbers of CFU/ml   the SEM of viable bacteria (tripli-
cate samples). Asterisks (*) indicate P values  0.01 as compared with co-
cultures containing naive spleen cells. These results are representative of
three experiments of similar design.T
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recognize lipid antigens. For example, Stenger et al. have
previously shown that human double negative T cell clones
can lyse Mycobacterium tuberculosis–infected macrophages in
a FasL-dependent manner; however, this activity had no
direct effect on the viability or growth of the mycobacteria
(28, 29). Our experiments to date indicate that both per-
forin and Fas–FasL interactions have minimal contributions
to the course of LVS infection or to intracellular growth
control (unpublished data). A handful of other studies have
shown that various populations of double negative T cells
can either expand (30, 31), or express Th1-type cytokines
(31, 32), in response to an in vivo challenge with intracel-
lular bacteria or viruses.
Importantly, the existence of double negative    T cells
that have an in vivo role in secondary immunity to LVS in-
fection has already been implicated in previous studies. Si-
multaneous depletion of CD4  and CD8  T cells during a
secondary LVS challenge had little effect on the outcome
of infection; the mice survived and cleared the infection,
albeit at a slower rate than wild-type mice (11, 12). Conlan
et al. found that although the CD4  and CD8  T cells
in these mice were successfully depleted, a substantial
Thy1 CD4 CD8  population of cells remained (12). Sim-
ilarly, studies in the murine Listeria model also indicate a
major role for such cells in secondary protection (33). The
precise origin, phenotype, role, and mechanism of action of
these cells in Francisella infection are therefore the subjects
of ongoing study in our lab. Such studies should help to
further define correlates of protective immunity for future
vaccine candidates.
We are grateful to our CBER colleagues Dr. Ronald Rabin and
Dr. Suzanne Epstein, and to Dr. Dragana Jankovic (NIAID/NIH),
for their thorough and thoughtful reviews of the manuscript, and to
Ms. Elizabeth Hamilton for excellent technical assistance.
Submitted: 28 April 2003
Accepted: 23 May 2003
References
1. Tarnvik, A. 1989. Nature of protective immunity to Fran-
cisella tularensis. Rev. Infect. Dis. 11:440–451.
2. Dennis, D.T., T.V. Inglesby, D.A. Henderson, J.G. Bartlett,
M.S. Ascher, E. Eitzen, A.D. Fine, A.M. Friedlander, J.
Hauer, M. Layton, et al. 2001. Tularemia as a biological
weapon: medical and public health management. JAMA.
285:2763–2773.
3. Eigelsbach, H.T., and C.M. Downs. 1961. Prophylactic ef-
fectiveness of live and killed tularemia vaccines. J. Immunol.
87:415–425.
4. Elkins, K.L., S.C. Cowley, and C.M. Bosio. 2003. Innate and
adaptive immune responses to an intracellular bacterium,
Francisella tularensis live vaccine strain. Microbes Infect. 5:132–
142.
5. Tarnvik, A., M. Eriksson, G. Sandstrom, and A. Sjostedt.
1992. Francisella tularensis - a model for studies of the immune
response to intracellular bacteria in man. Immunology. 76:349–
354.
6. Fortier, A.H., M.V. Slayter, R. Ziemba, M.S. Meltzer, and
C.A. Nacy. 1991. Live vaccine strain of Francisella tularensis:
infection and immunity in mice. Infect. Immun. 59:2922–
2928.
7. Elkins, K.L., R.K. Winegar, C.A. Nacy, and A.H. Fortier.
1992. Introduction of Francisella tularensis at skin sites induces
resistance to infection and generation of protective immu-
nity. Microb. Pathog. 13:417–421.
8. Leiby, D.A., A.H. Fortier, R.M. Crawford, R.D. Schreiber,
and C.A. Nacy. 1992. In vivo modulation of the murine im-
mune response to Francisella tularensis LVS by administration
of anticytokine antibodies. Infect. Immun. 60:84–89.
9. Sjostedt, A., R.J. North, and J.W. Conlan. 1996. The re-
quirement of tumour necrosis factor-alpha and interferon-
gamma for the expression of protective immunity to second-
ary murine tularaemia depends on the size of the challenge
inoculum. Microbiology. 142:1369–1374.
10. Bosio, C.M., and K.L. Elkins. 2001. Susceptibility to second-
ary Francisella tularensis LVS infection in B cell deficient mice
is associated with neutrophilia but not with defects in specific
T cell mediated immunity. Infect. Immun. 69:194–203.
11. Yee, D., T.R. Rhinehart-Jones, and K.L. Elkins. 1996. Loss
of either CD4  or CD8  T cells does not affect the magni-
tude of protective immunity to an intracellular pathogen,
Francisella tularensis strain LVS. J. Immunol. 157:5042–5048.
12. Conlan, J.W., A. Sjostedt, and R.J. North. 1994. CD4  and
CD8  T-cell-dependent and -independent host defense
mechanisms can operate to control and resolve primary and
secondary Francisella tularensis LVS infection in mice. Infect.
Immun. 62:5603–5607.
13. Green, L.C., A. Wagner, J. Glogowski, P.L. Skipper, J.S.
Wishnok, and S.R. Tannenbaum. 1982. Analysis of nitrate,
nitrite, and [15N]nitrate in biological fluids. Anal. Biochem.
126:131–138.
14. Fortier, A.H., T. Polsinelli, S.J. Green, and C.A. Nacy. 1992.
Activation of macrophages for destruction of Francisella tula-
rensis: identification of cytokines, effector cells, and effector
molecules. Infect. Immun. 60:817–825.
15. Green, S.J., C.A. Nacy, R.D. Schreiber, D.L. Granger, R.M.
Crawford, M.S. Meltzer, and A.H. Fortier. 1993. Neutraliza-
tion of gamma interferon and tumor necrosis factor alpha
blocks in vivo synthesis of nitrogen oxides from L-arginine
and protection against Francisella tularensis infection in Myco-
bacterium bovis BCG-treated mice. Infect. Immun. 61:689–698.
16. Elkins, K.L., T. Rhinehart-Jones, C.A. Nacy, R.K. Winegar,
and A.H. Fortier. 1993. T-cell-independent resistance to in-
fection and generation of immunity to Francisella tularensis. In-
fect. Immun. 61:823–829.
17. Elkins, K.L., T.R. Rhinehart-Jones, S.J. Culkin, D. Yee, and
R.K. Winegar. 1996. Minimal requirements for murine resis-
tance to infection with Francisella tularensis LVS. Infect. Im-
mun. 64:3288–3293.
18. Schaible, U.E., H.L. Collins, and S.H. Kaufmann. 1999.
Confrontation between intracellular bacteria and the immune
system. Adv. Immunol. 71:267–377.
19. Harty, J.T., and M.J. Bevan. 1995. Specific immunity to Lis-
teria monocytogenes in the absence of IFN . Immunity. 3:109–
117.
20. White, D.W., V.P. Badovinac, G. Kollias, and J.T. Harty.
2000. Cutting edge: antilisterial activity of CD8  T cells de-
rived from TNF-deficient and TNF/perforin double-defi-
cient mice. J. Immunol. 165:5–9.
21. Badovinac, V.P., and J.T. Harty. 2000. Adaptive immunity
and enhanced CD8  T cell response to Listeria monocytogenesT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
389 Cowley and Elkins
in the absence of perforin and IFN-gamma. J. Immunol. 164:
6444–6452.
22. Ruuls, S.R., R.M. Hoek, V.N. Ngo, T. McNeil, L.A. Lu-
cian, M.J. Janatpour, H. Korner, H. Scheerens, E.M. Hessel,
J.G. Cyster, et al. 2001. Membrane-bound TNF supports
secondary lymphoid organ structure but is subservient to se-
creted TNF in driving autoimmune inflammation. Immunity.
15:533–543.
23. Olleros, M.L., R. Guler, N. Corazza, D. Vesin, H.-P. Eug-
ster, G. Marchal, P. Chavarot, C. Mueller, and I. Garcia.
2002. Transmembrane TNF induces an efficient cell-medi-
ated immunity and resistance to Mycobacterium bovis bacillus
Calmette-Guerin infection in the absence of secreted TNF
and lymphotoxin-alpha. J. Immunol. 168:3394–3401.
24. Roach, D.R., A.G. Bean, C. Demangel, M.P. France, H.
Briscoe, and W.J. Britton. 2002. TNF regulates chemokine
induction essential for cell recruitment, granuloma formation,
and clearance of mycobacterial infection. J. Immunol. 168:
4620–4627.
25. Roach, D.R., H. Briscoe, B. Saunders, M.P. France, S. Rim-
inton, and W.J. Britton. 2001. Secreted lymphotoxin-alpha is
essential for the control of an intracellular bacterial infection.
J. Exp. Med. 193:239–246.
26. Cohen, P.L., and R.A. Eisenberg. 1991. Lpr and gld: single
gene models of systemic autoimmunity and lymphoprolifera-
tive disease. Annu. Rev. Immunol. 9:243–269.
27. MacDonald, H.R. 1995. NK1.1  T cell receptor-alpha/
beta  cells: new clues to their origin, specificity, and func-
tion. J. Exp. Med. 182:633–638.
28. Stenger, S., D.A. Hanson, R. Teitelbaum, P. Dewan, K.R.
Niazi, C.J. Froelich, T. Ganz, S. Thoma-Uszynski, A. Me-
lian, C. Bogdan, et al. 1998. An antimicrobial activity of cy-
tolytic T cells mediated by granulysin. Science. 282:121–125.
29. Stenger, S., R.J. Mazzaccaro, K. Uyemura, S. Cho, P.F.
Barnes, J.-P. Rosat, A. Sette, M.B. Brenner, S.A. Procelli,
B.R. Bloom, and R.L. Modlin. 1997. Differential effects of
cytolytic T cell subsets on intracellular infection. Science. 276:
1684–1687.
30. Phyu, S., S. Sornes, T. Mustafa, A. Tadesse, R. Jonsson, and
G. Bjune. 1999. Changes in T-lymphocyte subsets in lungs
and spleens of mice with slowly progressive primary Mycobac-
terium tuberculosis infection: involvement of unconventional
T-cell subsets. Scand. J. Immunol. 50:137–144.
31. Hossain, M.S., H. Takimoto, T. Ninomiya, H. Yoshida, K.
Kishihara, G. Matsuzaki, G. Kimura, and K. Nomoto. 2000.
Characterization of CD4-CD8-CD3  T-cell receptor-alpha-
beta  T cells in murine cytomegalovirus infection. Immunol-
ogy. 101:19–29.
32. Kadena, T., G. Matsuzaki, S. Fujise, K. Kishihara, H. Taki-
moto, M. Sasaki, M. Beppu, S. Nakamura, and K. Nomoto.
1997. TCR alpha beta  CD4  CD8  T cells differentiate ex-
trathymically in an lck-independent manner and participate
in early response against Listeria monocytogenes infection
through interferon-gamma production. Immunology. 91:511–
519.
33. Dunn, P.L., and R.J. North. 1991. Resolution of primary
murine listeriosis and acquired resistance to lethal secondary
infection can be mediated predominatly by Thy-1  CD4 
CD8  cells. J. Infect. Dis. 164:869–877.